JPWO2024241468A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2024241468A5
JPWO2024241468A5 JP2024529314A JP2024529314A JPWO2024241468A5 JP WO2024241468 A5 JPWO2024241468 A5 JP WO2024241468A5 JP 2024529314 A JP2024529314 A JP 2024529314A JP 2024529314 A JP2024529314 A JP 2024529314A JP WO2024241468 A5 JPWO2024241468 A5 JP WO2024241468A5
Authority
JP
Japan
Prior art keywords
inhibitor
combination
treating
clostridium butyricum
ferm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024529314A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2024241468A1 (https=
JP7590713B1 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2023/019078 external-priority patent/WO2024241468A1/ja
Application granted granted Critical
Publication of JP7590713B1 publication Critical patent/JP7590713B1/ja
Publication of JPWO2024241468A1 publication Critical patent/JPWO2024241468A1/ja
Publication of JPWO2024241468A5 publication Critical patent/JPWO2024241468A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024529314A 2023-05-23 2023-05-23 がん治療用組み合わせ医薬 Active JP7590713B1 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2023/019078 WO2024241468A1 (ja) 2023-05-23 2023-05-23 がん治療用組み合わせ医薬

Publications (3)

Publication Number Publication Date
JP7590713B1 JP7590713B1 (ja) 2024-11-27
JPWO2024241468A1 JPWO2024241468A1 (https=) 2024-11-28
JPWO2024241468A5 true JPWO2024241468A5 (https=) 2025-04-30

Family

ID=93588015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529314A Active JP7590713B1 (ja) 2023-05-23 2023-05-23 がん治療用組み合わせ医薬

Country Status (4)

Country Link
EP (1) EP4717274A1 (https=)
JP (1) JP7590713B1 (https=)
CN (1) CN121152637A (https=)
WO (1) WO2024241468A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121177212B (zh) * 2025-11-25 2026-03-03 中南大学湘雅二医院 一种用于治疗egfr突变非小细胞肺癌脑膜转移的药物、应用、药盒及药物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08252088A (ja) 1995-03-17 1996-10-01 Nippo Kagaku Kk クロストリジウム属細菌の培養方法
JP2009269836A (ja) * 2008-05-01 2009-11-19 Miyarisan Pharmaceutical Co Ltd 大腸癌細胞増殖抑制物質
US20220280601A1 (en) * 2019-07-31 2022-09-08 Momotaro-Gene Inc. METHOD FOR TREATMENT OF HEPATIC CANCER USING REIC/Dkk-3 GENE IN COMBINATION WITH ANTI-TUMOR AGENT
US12589123B2 (en) 2020-04-21 2026-03-31 City Of Hope Compositions and methods comprising clostridium butyricum for the treatment of cancer

Similar Documents

Publication Publication Date Title
Cohen et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in relapsed/refractory multiple myeloma
Trudel et al. Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study
Li et al. Exploring the modulatory effects of gut microbiota in anti-cancer therapy
Johnson et al. Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis
Harvey et al. Critical shortage in BCG immunotherapy: how did we get here and where will it take us?
Richardson et al. Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma
Bejar et al. Therapy of advanced squamous cell carcinoma of the skin
JP2021521247A5 (https=)
JP2024527109A5 (https=)
JP2021509395A5 (https=)
JP2019526559A5 (https=)
Pavia et al. Clinical implications of nicotine as an antimicrobial agent and immune modulator
JPWO2024241468A5 (https=)
JP2021512921A5 (https=)
Ning et al. Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study
Gao et al. LB0009 allogenic CD19 CAR NK cell therapy in refractory systemic lupus erythematosus-a case series study
Mato et al. A phase Ia/Ib study exploring the synthetic lethality of the orally administered novel BTK inhibitor, Dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide in patients with relapsed/refractory CLL, DLBCL or other B-cell lymphomas
Obeid et al. Cutaneous lesion induced by a subcutaneous administration of bortezomib
Kastritis et al. Thalidomide in the treatment of multiple myeloma
Mueller et al. Update on monocentric CD19-CAR T-Cell therapy in 30 patients with autoimmune disease
Berenson et al. A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).
Richardson et al. A Phase 1/2 Multi-Center, Randomized, Open Label Dose Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide and Bortezomib.
Huizinga et al. OP0042 Clinical and Radiographic Outcomes at Two Years and the Effect of Tocilizumab (TCZ) Discontinuation Following Sustained Remission in the Second Year of the Act-Ray Study
Szczepanek et al. Long-term outcomes of imatinib real-life treatment for chronic myeloid leukemia-a 20-year review
TW201914596A (zh) 腸道益生菌用於製備抑制大腸直腸癌細胞遷移的醫藥組合物的用途